CN103462958A - Application of Incarviatone A in medicaments for treating tongue cancer - Google Patents
Application of Incarviatone A in medicaments for treating tongue cancer Download PDFInfo
- Publication number
- CN103462958A CN103462958A CN 201310432309 CN201310432309A CN103462958A CN 103462958 A CN103462958 A CN 103462958A CN 201310432309 CN201310432309 CN 201310432309 CN 201310432309 A CN201310432309 A CN 201310432309A CN 103462958 A CN103462958 A CN 103462958A
- Authority
- CN
- China
- Prior art keywords
- incarviatone
- medicaments
- tongue cancer
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UKERFPVDLCMTKF-FAPYOACPSA-N CC[C@](C)(CC[C@@H]1[C@]2(C)OCC1)O[C@H]([C@@](C)([C@H](C)C1)c(c([C@@H]3O)c4)c1cc4C1=C(C=O)C(C)=CC1)[C@]23O Chemical compound CC[C@](C)(CC[C@@H]1[C@]2(C)OCC1)O[C@H]([C@@](C)([C@H](C)C1)c(c([C@@H]3O)c4)c1cc4C1=C(C=O)C(C)=CC1)[C@]23O UKERFPVDLCMTKF-FAPYOACPSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Incarviatone A in preparation of medicaments for treating tongue cancer, and belongs to the technical field of a new application of medicaments. In-vitro methyl thiazolyl tetrazolium (MTT) anti-tumor activity evaluation discovers that the Incarviatone A has a prominent inhibiting effect on growth of human tongue cancer cell strains Tca8113 and T6. Therefore, the Incarviatone A can be used for preparing anti-tongue cancer medicaments, and has a good development and application prospect. The application of the Incarviatone A in preparation of the medicaments for treating the tongue cancer is made public for the first time, the skeleton type is completely novel, and the Incarviatone A has an unexpectedly strong tongue cancer cell inhibiting activity.
Description
Technical field
The present invention relates to the new purposes of Compound I ncarviatone A, relate in particular to the application of Incarviatone A in the anti-carcinoma of tongue medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be the natural product or derivatives thereof, as paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, searching anticancer compound or lead compound have great importance.
The Compound I ncarviatone A the present invention relates to is one and within 2012, delivers (Shen, Y. H. et al., 2012. Incarviatone A, a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi, and its absolute configuration via calculated electronic circular dichroic spectra. RSC Advances 2, 4175 – 4180.) New skeleton compound, this compound has brand-new framework types, there is no at present the report about this compound activity aspect, purposes for the Incarviatone A the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for carcinoma of tongue simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of Compound I ncarviatone A in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Incarviatone A in the anti-carcinoma of tongue medicine of preparation, and the structural formula of Incarviatone A is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Incarviatone A also has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6, suppresses the IC of this 2 strain Growth of Cells
50value is respectively 1.95 ± 0.33 μ M and 3.27 ± 0.26 μ M.Therefore, Incarviatone A can, for the preparation of anti-carcinoma of tongue medicine, have good development prospect.
The purposes of the Incarviatone A the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for carcinoma of tongue simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of Compound I ncarviatone A involved in the present invention is referring to document (Shen, Y. H. et al., 2012. Incarviatone A, a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi, and its absolute configuration via calculated electronic circular dichroic spectra. RSC Advances 2,4175 – 4180.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of Compound I ncarviatone A tablet involved in the present invention:
Get 20 and digest compound Incarviatone A, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of Compound I ncarviatone A capsule involved in the present invention:
Get 20 and digest compound Incarviatone A, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Incarviatone A to the strain of people's Human Tongue Carcinoma Lines
1. method: in the cell of growth logarithmic (log) phase: people's Human Tongue Carcinoma Lines strain Tca8113 and T6(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4the concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that the drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Incarviatone A of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Incarviatone A has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.This compound suppresses the IC of people Human Tongue Carcinoma Lines strain Tca8113 and T6 growth
50value is respectively: 1.95 ± 0.33 μ M and 3.27 ± 0.26 μ M.
By above-described embodiment, shown, Incarviatone A of the present invention has good inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.Prove thus, Incarviatone A of the present invention has anti-carcinoma of tongue activity, can be for the preparation of anti-carcinoma of tongue medicine.
Claims (1)
1.Incarviatone the application of A in treatment carcinoma of tongue medicine, described Compound I ncarviatone A structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310432309 CN103462958A (en) | 2013-09-22 | 2013-09-22 | Application of Incarviatone A in medicaments for treating tongue cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310432309 CN103462958A (en) | 2013-09-22 | 2013-09-22 | Application of Incarviatone A in medicaments for treating tongue cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103462958A true CN103462958A (en) | 2013-12-25 |
Family
ID=49788156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310432309 Pending CN103462958A (en) | 2013-09-22 | 2013-09-22 | Application of Incarviatone A in medicaments for treating tongue cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462958A (en) |
-
2013
- 2013-09-22 CN CN 201310432309 patent/CN103462958A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462960A (en) | Application of Incarviatone A in medicaments for treating prostatic cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN103432140A (en) | Application of Chukrasone A in preparation of medicaments for treating endometrial cancer | |
| CN103316008A (en) | Application of Aspeverin in preparation of medicine for treating rectal cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN103462958A (en) | Application of Incarviatone A in medicaments for treating tongue cancer | |
| CN103462961A (en) | Application of Incarviatone A in medicaments for treating bladder cancer | |
| CN103462969A (en) | Application of Incarviatone A in medicaments for treating breast cancer | |
| CN103462966A (en) | Application of Incarviatone A in medicaments for treating colorectal cancer | |
| CN103462971A (en) | Application of Incarviatone A in medicaments for treating kidney cancer | |
| CN103462974A (en) | Application of Incarviatone A in medicaments for treating ovarian cancer | |
| CN103432116A (en) | Application of Chukrasone B in medicament for treating tongue cancer | |
| CN103446088A (en) | Application of Incarviatone A in skin cancer treatment drug | |
| CN103446091A (en) | Application of Incarviatone A in laryngeal cancer treatment drug | |
| CN103446092A (en) | Application of Incarviatone A in cervical cancer treatment drug | |
| CN103446089A (en) | Application of Incarviatone A in nasopharynx cancer treatment drug | |
| CN103446087A (en) | Application of Incarviatone A in endometrial cancer treatment drug | |
| CN103446133A (en) | Application of Lycojaponicumin B in tongue cancer treatment drug | |
| CN103356568A (en) | Application of Sarcaboside A in preparing medicine for treating tongue cancer | |
| CN103446084A (en) | Application of Incarviatone A in pancreatic cancer treatment drug | |
| CN103462964A (en) | Application of Incarviatone A in medicaments for treating bile duct cancer | |
| CN103120679A (en) | Application of Aphanamixoid A in medicine for treating tongue cancer | |
| CN103462959A (en) | Application of Incarviatone A in medicaments for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131225 |